Skip to main content
×
Home
    • Aa
    • Aa

Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination

  • A. I. SOIPE (a1), H. RAZAVI (a2), D. RAZAVI-SHEARER (a2), O. GALÁRRAGA (a3), L. E. TAYLOR (a4) and B. D. L. MARSHALL (a1)...
Abstract
SUMMARY

We utilized a disease progression model to predict the number of viraemic infections, cirrhotic cases, and liver-related deaths in the state of Rhode Island (RI) under four treatment scenarios: (1) current HCV treatment paradigm (about 215 patients treated annually, Medicaid reimbursement criteria fibrosis stage ⩾F3); (2) immediate scale-up of treatment (to 430 annually) and less restrictive Medicaid reimbursement criteria (fibrosis stage ⩾F2); (3) immediate treatment scale-up and no fibrosis stage-specific Medicaid reimbursement criteria (⩾F0); (4) an ‘elimination’ scenario (i.e. a continued treatment scale-up needed to achieve >90% reduction in viraemic cases by 2030). Under current treatment models, the number of cirrhotic cases and liver-related deaths will plateau and peak by 2030, respectively. Treatment scale-up with ⩾F2 and ⩾F0 fibrosis stage treatment criteria could reduce the number of cirrhotic cases by 21·7% and 10·0%, and the number of liver-related deaths by 19·3% and 7·4%, respectively by 2030. To achieve a >90% reduction in viraemic cases by 2030, over 2000 persons will need to be treated annually by 2020. This strategy could reduce cirrhosis cases and liver-related deaths by 78·9% and 72·4%, respectively by 2030. Increased HCV treatment uptake is needed to substantially reduce the burden of HCV by 2030 in Rhode Island.

Copyright
Corresponding author
*Author for correspondence: B. D. L. Marshall, PhD, Manning Assistant Professor of Epidemiology, Department of Epidemiology, Brown University School of Public Health, 121 South Main Street, Box G-S-121-2, Providence, RI, 02912, USA. (Email: brandon_marshall@brown.edu)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1. MM Denniston , Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010. Annals of Internal Medicine 2014; 160: 293300.

2. IM Jacobson , Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clinical Gastroenterology and Hepatology 2010; 8: 924933.

3. RM Klevens , Evolving epidemiology of hepatitis C virus in the United States. Clinical Infectious Diseases 2012; 55: S3S9.

4. KN Ly , Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clinical Infectious Diseases 2016; 62: 12871288.

5. H Razavi , Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 21642170.

7. ML Shiffman . Hepatitis C virus therapy in the direct acting antiviral era. Current Opinion in Gastroenterology 2014; 30: 217222.

8. MD Stein , J Maksad , J Clarke . Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence 2001; 61: 211215.

9. CE McGowan , MW Fried . Barriers to hepatitis C treatment. Liver International 2012; 32: 151156.

10. JW Ward , DB Rein , BD Smith . Data to guide the ‘test and treat era’ of hepatitis C. Gastroenterology 2012; 143: 887889.

11. M Kabiri , The changing burden of hepatitis C virus infection in the United States: Model-based predictions. Annals of Internal Medicine 2014; 161: 170180.

12. S Barua , Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine 2015; 163: 215223.

13. JT Nguyen , A budget impact analysis of newly available hepatitis C therapeutics and the financial burden on a state correctional system. Journal of Urban Health 2015; 92: 635649.

14. H Razavi , The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis 2014; 21: 3459.

20. HH Thein , Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 2008; 48: 418431.

22. K Sennfält , Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in sweden. Scandinavian Journal of Gastroenterology 2001; 36: 870876.

23. AJ Freeman , Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809816.

24. B Fu , W Wang , X Shi . Impact of delayed diagnosis time in estimating progression rates to hepatitis C virus-related cirrhosis and death. Statistical Methods in Medical Research 2015; 24: 693710.

25. JM Micallef , JM Kaldor , GJ Dore . Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. Journal of Viral Hepatitis 2006; 13: 3441.

30. S Onofrey , Underascertainment of acute hepatitis C virus infections in the U.S. Surveillance system: a case series and chart review. Annals of Internal Medicine 2015; 163: 254261.

31. BR Edlin , Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62: 13531363.

32. SD Holmberg , Hepatitis C in the United States. New England Journal of Medicine 2013; 368: 18591861.

34. GL Davis , Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513521.

35. P Bruggmann , Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of Viral Hepatitis 2014; 21: 533.

36. ML Volk , Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 17501755.

37. D Kershenobich , Applying a system approach to forecast the total hepatitis C virus-infected population size: Model validation using US data. Liver International 2011; 31: 417.

40. S Boccato , Fibrosis progression in initially mild chronic hepatitis C. Journal of Viral Hepatitis 2006; 13: 297302.

43. R Mahajan , Mortality among persons in care with hepatitis C virus infection: The chronic hepatitis cohort study (CHeCS), 2006–2010. Clinical Infectious Diseases 2014; 58: 10551061.

44. R Sacks-Davis , Hepatitis C virus reinfection and spontaneous clearance of reinfection – the inc3 study. Journal of Infectious Diseases 2015; 212: 14071419.

46. B Müllhaupt , Modeling the health and economic burden of hepatitis C virus in switzerland. PLoS ONE 2015; 10: e0125214.

47. HS Chahal , Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Internal Medicine 2016; 176: 6573.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
WORD
Supplementary Materials

Soipe supplementary material
Soipe supplementary material 1

 Word (207 KB)
207 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 18
Total number of PDF views: 79 *
Loading metrics...

Abstract views

Total abstract views: 392 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd March 2017. This data will be updated every 24 hours.